
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **March 5, 2019**

TABULA RASA HEALTHCARE, INC.

(Exact Name of Registrant Specified in Charter)

Delaware
(State or Other
Jurisdiction of
Incorporation)

001-37888
(Commission File
Number)

46-5726437
(I.R.S. Employer
Identification No.)

228 Strawbridge Drive, Suite 100
Moorestown, New Jersey
(Address of Principal Executive Offices)

08057
(Zip Code)

Registrant's telephone number, including area code: **(866) 648-2767**

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On March 5, 2019, the Board of Directors (the “Board”) of Tabula Rasa HealthCare, Inc. (the “Company”) increased the size of the Board from eight directors to nine directors and appointed Rear Admiral (“RADM”) Pamela Schweitzer, Pharm.D., as a director of the Board. RADM Schweitzer will serve as a Class II director, to serve until the 2021 annual meeting of stockholders or until her earlier resignation, retirement or other termination of service. In connection with the adoption of a revised Board committee structure (as described below), the Board named RADM Schweitzer to serve as a member of each of the Nominating Committee and the Corporate Governance Committee. The Board has determined that RADM Schweitzer is an independent director in accordance with applicable rules of the Securities and Exchange Commission (the “SEC”) and the Nasdaq Stock Market. RADM Schweitzer will be compensated in accordance with the non-employee director compensation program of the Board, as described in the Company’s Proxy Statement filed with the SEC on May 1, 2018.

RADM Schweitzer, 59, has undertaken various speaking engagements since September 2018. Previously, she served as the Assistant Surgeon General and Chief Pharmacist Officer of the U.S. Public Health Service (“PHS”) from August 2014 through September 2018. RADM Schweitzer served as a technical director in two divisions of the U.S. Centers for Medicare and Medicaid Services (“CMS”) from February 2013 to August 2018. Over the course of her career, RADM Schweitzer has served in varied assignments in the U.S. Indian Health Service (“IHS”), U.S. Veterans Administration and with the CMS. RADM Schweitzer earned her Doctor of Pharmacy from the University of California San Francisco School of Pharmacy and holds a Bachelor’s degree in Biological Sciences from California State University Fullerton. She completed an Ambulatory Care/Administrative Residency at University of California Irvine Medical Center and is a Board Certified Ambulatory Care Pharmacist. She is currently completing the Executive Master of Health Administration Program at the University of Southern California Sol Price School of Public Policy. The Board believes that RADM Schweitzer’s extensive leadership experience in public service and expertise in pharmacy programs will make her a valuable member of the Company’s Board.

In connection with her appointment, RADM Schweitzer will enter into the Company’s standard indemnification agreement, the form of which was previously filed with the Company’s Registration Statement on Form S-1 (Registration No. 333-208857) in connection with the Company’s initial public offering completed in October 2016. There is no other material Company plan, contract or arrangement in which RADM Schweitzer will participate in connection with her appointments. There are no arrangements or understandings between RADM Schweitzer and any other person pursuant to which RADM Schweitzer was selected as a director of the Company, and there is no family relationship between RADM Schweitzer and any of the Company’s other directors or executive officers. There are also no related party transactions between either of RADM Schweitzer and the Company.

Item 7.01 Regulation FD Disclosure.

On March 6, 2019, the Company issued a press release announcing RADM Schweitzer’s appointment to the Board. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

The information provided in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed to be incorporated by reference in any filing made by the Company pursuant to the Securities Act or the Exchange Act other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.

Item 8.01 Other Events

At its meeting held on March 5, 2019, the Board approved a revised Board committee structure that terminates the existing Nominating and Corporate Governance Committee and designates a separate Nominating Committee and Corporate Governance Committee. The revised Board committee structure and related committee membership changes became effective immediately. As of March 5, 2019, the Board will have the following standing committees: Audit Committee, Compensation Committee, Nominating Committee and Corporate Governance Committee.

In addition to approving the revised Board committee structure, the Board approved a Nominating Committee charter and a Corporate Governance Committee charter to replace the former Nominating and Corporate Governance Committee charter and set forth the responsibilities of each respective committee. The Company will post copies of the new Nominating Committee charter and Corporate Governance Committee charter in the "Corporate Governance" section of the "Investors" page of its corporate website at www.tabularasahealthcare.com.

In connection with the implementation of the revised Board Committee structure, the Board also made several appointments and changes in committee membership. The membership of each Board committee is as follows:

Nominating Committee

Dennis Helling (chairperson)
Jan Berger
RADM Pamela Schweitzer

Audit Committee

Michael Purcell (chairperson)
A Gordon Tunstall
Samira Beckwith

Corporate Governance Committee

A Gordon Tunstall (chairperson)
Samira Beckwith
Jan Berger
Dennis Helling
Kathrine O'Brien
Michael Purcell
RADM Pamela Schweitzer

Compensation Committee

Samira Beckwith (chairperson)
Kathrine O'Brien
Jan Berger

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press release of Tabula Rasa HealthCare, Inc. issued March 6, 2019

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TABULA RASA HEALTHCARE, INC.

By: /s/ Dr. Calvin H. Knowlton
Dr. Calvin H. Knowlton
Chief Executive Officer

Dated: March 6, 2019



Tabula Rasa HealthCare Appoints New Member to its Board of Directors

Rear Admiral Pamela Schweitzer, PharmD Joins Board of Medication Safety Company

Moorestown, NJ (March 6, 2019) - Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, appointed former Assistant Surgeon General and Chief Pharmacist of the United States Public Health Service (PHS), Rear Admiral (RADM) Pamela Schweitzer, PharmD to its Board of Directors. The appointment occurred at the TRHC Board of Directors meeting held March 4-5, 2019, and was effective immediately. The TRHC Board now includes nine members with a majority of five women and four men.

As Chief Pharmacist Officer for PHS, RADM Schweitzer was responsible for providing leadership and coordination of PHS's pharmacy programs and professional affairs for the Office of the Surgeon General and the Department of Health & Human Services. Prior, she served with the Centers for Medicare and Medicaid Services and held varied assignments in the Indian Health Service (IHS) and U.S. Veterans Administration.

"RADM Schweitzer is a thought leader in the field of pharmacotherapy, and her experience with large policy development organizations concerned with population health, particularly focused on medication management, will help TRHC maintain its position as a vanguard in the field of medication safety," stated TRHC Chairman and CEO Calvin H. Knowlton, PhD. "The Board believes RADM Schweitzer's extensive leadership experience in public service and expertise in pharmacy programs will make her a valuable member of TRHC's Board."

RADM Schweitzer has received numerous honors for her leadership and contributions to pharmacy, including the 2014 American Pharmacists Association Distinguished Federal Pharmacist Award, the 2012 USPHS Mary Louise Anderson Leadership Award, and the IHS Senior Pharmacist of the Year 2013 Award.

RADM Schweitzer will serve as a Class II independent director, to serve until the 2021 annual meeting of stockholders or until her earlier resignation, retirement or other termination of service. Her appointment increases the size of the Board from eight to nine members.

RADM Schweitzer received her Bachelor's degree in Biological Sciences from California State University Fullerton (CSUF), earned her Doctor of Pharmacy from the University of California San Francisco (UCSF) School of Pharmacy, completed an Ambulatory Care/Administrative Residency at University of California Irvine Medical Center and is a Board Certified Ambulatory Care Pharmacist (BCACP). She currently is completing the Executive Master of Health Administration (EMHA) Program at the University of Southern California (USC) Sol Price School of Public Policy.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize patient outcomes, lower healthcare costs and improve organizational performance. Medication risk management is TRHC's lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com. Follow us on Twitter @TabulaRasaHC for up-to-date information.

Contact:**Media**

Dianne Semingson
dsemingson@TRHC.com
T: 215-870-0829

Investor

Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500
tabularasa@westwicke.com
